Xenon Pharma Q2 net loss $31.2M; XEN1101 Phase 3 on track for H2 2022

Xenon Pharmaceuticals Inc.

2022-Q2 EPS reported -$0.91 revenue$9,302,000

Net loss of $31.2M for Q2 2022, up from $22.1M in Q2 2021.
Cash and securities $788.2M as of June 30, 2022, extended runway into 2026.
Revenue fell to $0.5M from $2.2M, mainly due to wind-down of Neurocrine collaboration.
XEN1101 Phase 3 X-TOLE2 expected to start in H2 2022 after positive FDA End-of-Phase 2 meeting.
XEN496 EPIK study for KCNQ2-DEE anticipated to complete in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.